Hepatoprotective Measures for Children at High Risk of Non Alcoholic Fatty Liver Disease

NCT06918080 Phase 4 ACTIVE_NOT_RECRUITING

Non Alcoholic Fatty Liver Disease (NAFLD) is a spectrum of disease, ranging from simple fatty deposition (steatosis) to inflammation (steatohepatitis), fibrosis, cirrhosis, and end-stage liver failure. In childhood, it may be associated with a metabolic syndrome or with obesity, or even in normal children. Liver biopsy has always been the gold standard method for diagnosing and staging NAFLD. However, the urge of non-invasive biomarkers or imaging techniques has been recommended. This study will evaluate the use of the LIVERFASt biomarkers for early detection and staging of NAFLD.

Details

Lead sponsor	Ain Shams University
Phase	Phase 4
Status	ACTIVE_NOT_RECRUITING
Enrolment	200
Start date	2023-11-19
Completion	2025-07

Conditions

• Non Alcoholic Fatty Liver Diseases (NAFLD)
• Obesity and Overweight
• Acute Lymphoblastic Leukemia

Interventions

• Ursodeoxycholic Acid 250 Mg Oral Capsule
• Omega -3 fatty acids
• Physical exercise
• Mediterrenean diet
• Diet according to NASPGHAN guidelines

Primary outcomes

• Study of the prevalence of liver steatosis, steatohepatitis and fibrosis among the study population by using LIVERFASt. — 2 years
  Study of the prevalence of liver steatosis, steatohepatitis and fibrosis among the study population by using LIVERFASt.

Countries

Egypt